[Executive Summary & Highlights](index=1&type=section&id=1_Executive_Summary_Highlights) AptarGroup delivered strong financial results for both Q2 and year-to-date 2025, marked by sales growth, increased profitability, and significant shareholder returns [Second Quarter 2025 Highlights](index=1&type=section&id=1.1_Second_Quarter_2025_Highlights) AptarGroup reported strong second quarter 2025 results with positive contributions from all segments, particularly Pharma and Closures, driven by increased volumes and sales of higher value products. The company also returned $100 million to shareholders through dividends and share repurchases Second Quarter 2025 Key Financial Highlights | Metric | Value | Change (YoY) | | :-------------------------- | :---------- | :----------- | | Reported Sales Growth | 6% | +6% | | Core Sales Growth | 3% | +3% | | Reported Net Income | $112 million | +24% | | Adjusted EBITDA | $218 million | +13% | | Adjusted EBITDA Margin | 22.6% | +140 bps | | Reported Earnings Per Share | $1.67 | +25% | | Adjusted Earnings Per Share | $1.66 | +18% | | Shareholder Returns | $100 million | N/A | [Six Months Year-to-Date 2025 Highlights](index=1&type=section&id=1.2_Six_Months_Year_to_Date_2025_Highlights) For the first half of 2025, AptarGroup achieved reported and core sales growth of 2%, with significant increases in net income and adjusted EBITDA, and returned a total of $210 million to shareholders Six Months Year-to-Date 2025 Key Financial Highlights | Metric | Value | Change (YoY) | | :-------------------------- | :---------- | :----------- | | Reported Sales Growth | 2% | +2% | | Core Sales Growth | 2% | +2% | | Reported Net Income | $191 million | +10% | | Adjusted EBITDA | $402 million | +8% | | Reported Earnings Per Share | $2.83 | +10% | | Adjusted Earnings Per Share | $2.86 | +8% | | Shareholder Returns | $210 million | N/A | [Second Quarter 2025 Financial Results](index=1&type=section&id=2_Second_Quarter_2025_Financial_Results) AptarGroup's second quarter 2025 financial results show consolidated sales growth and strong performance across all segments, particularly Pharma and Closures [Consolidated Performance](index=1&type=section&id=2.1_Consolidated_Performance_Q2) AptarGroup's consolidated sales for Q2 2025 increased 6% to $966 million compared to the prior year, with core sales increasing 3%, demonstrating overall growth despite currency effects Second Quarter 2025 Consolidated Sales Analysis | Metric | Q2 2025 Sales | Q2 2024 Sales | Reported Sales Growth | Currency Effects | Acquisitions | Core Sales Growth | | :---------------- | :------------ | :------------ | :-------------------- | :--------------- | :----------- | :---------------- | | Total AptarGroup | $966 million | $910 million | 6% | (3)% | 0% | 3% | [Segment Performance](index=2&type=section&id=2.2_Segment_Performance_Q2) All Aptar segments contributed positively to Q2 2025 results, with Pharma and Closures driving growth through increased volumes and higher-value products, while Beauty saw modest core sales growth despite mixed market conditions [Aptar Pharma](index=2&type=section&id=2.2.1_Aptar_Pharma) Aptar Pharma achieved strong Q2 2025 sales and margin growth, driven by Prescription, Injectables, and Active Material Science - Reported sales increased **7%** and core sales increased **3%** in Q2 2025[7](index=7&type=chunk) - Growth was driven by strong demand in Prescription, Injectables (**9% core sales growth**), and Active Material Science (**11% core sales growth**), offsetting a decline in Consumer Healthcare[7](index=7&type=chunk) - Adjusted EBITDA margins grew **130 basis points to 35.4%**, aided by royalty revenues[7](index=7&type=chunk) [Aptar Beauty](index=2&type=section&id=2.2.2_Aptar_Beauty) Aptar Beauty reported modest core sales growth in Q2 2025, supported by personal care, despite challenges in beauty dispensing technologies - Reported sales increased **4%** and core sales were up **1%** in Q2 2025, primarily due to higher tooling sales for personal care and beauty end markets[8](index=8&type=chunk) - Strong growth in personal care products partially offset lower demand in beauty dispensing technologies for fragrance and full pack solutions, impacted by subdued new fragrance launches and tariff-related uncertainties[8](index=8&type=chunk) - Adjusted EBITDA margins increased by **20 basis points to 14.1%**[8](index=8&type=chunk) [Aptar Closures](index=2&type=section&id=2.2.3_Aptar_Closures) Aptar Closures delivered strong Q2 2025 sales and margin improvements, fueled by increased demand in food and beverage markets - Reported sales increased **8%** and core sales increased **7%** in Q2 2025[9](index=9&type=chunk) - Solid product sales growth was mainly driven by increased demand in the food and beverage end markets across almost every region and various applications[9](index=9&type=chunk) - Adjusted EBITDA margins improved by **130 basis points to 16.9%**[9](index=9&type=chunk) [Earnings Per Share and Tax Rate](index=2&type=section&id=2.3_Earnings_Per_Share_Tax_Rate_Q2) Aptar's Q2 2025 reported earnings per share increased 25% to $1.67, and adjusted earnings per share increased 18% to $1.66, benefiting from a lower effective tax rate of 20.0% due to tax planning and greater tax benefits from share-based compensation Second Quarter Earnings Per Share and Tax Rate | Metric | Q2 2025 | Q2 2024 | Change (YoY) | | :-------------------------- | :------ | :------ | :----------- | | Reported Earnings Per Share | $1.67 | $1.34 | +25% | | Adjusted Earnings Per Share | $1.66 | $1.41 | +18% | | Effective Tax Rate | 20.0% | 23.5% | -3.5 percentage points | [Six Months Year-to-Date 2025 Financial Results](index=2&type=section&id=3_Six_Months_Year_to_Date_2025_Financial_Results) AptarGroup's year-to-date 2025 financial results show consistent consolidated sales growth and increased profitability for the first half of the year [Consolidated Performance](index=2&type=section&id=3.1_Consolidated_Performance_YTD) For the six months ended June 30, 2025, AptarGroup's reported sales increased 2% to $1.85 billion, with core sales also up 2%, reflecting consistent growth across the company Six Months Year-to-Date 2025 Consolidated Sales Analysis | Metric | YTD 2025 Sales | YTD 2024 Sales | Reported Sales Growth | Currency Effects | Acquisitions | Core Sales Growth | | :---------------- | :------------- | :------------- | :-------------------- | :--------------- | :----------- | :---------------- | | Total AptarGroup | $1.85 billion | $1.83 billion | 2% | 0% | 0% | 2% | [Earnings Per Share and Tax Rate](index=2&type=section&id=3.2_Earnings_Per_Share_Tax_Rate_YTD) Aptar's year-to-date reported earnings per share increased 10% to $2.83, and adjusted earnings per share rose 8% to $2.86, with the effective tax rate for the period at 22.5% Six Months Year-to-Date Earnings Per Share and Tax Rate | Metric | YTD 2025 | YTD 2024 | Change (YoY) | | :-------------------------- | :------- | :------- | :----------- | | Reported Earnings Per Share | $2.83 | $2.57 | +10% | | Adjusted Earnings Per Share | $2.86 | $2.64 | +8% | | Effective Tax Rate | 22.5% | 22.1% | +0.4 percentage points | [Outlook and Shareholder Returns](index=3&type=section&id=4_Outlook_Shareholder_Returns) Aptar anticipates solid third-quarter 2025 performance, particularly in Pharma, while continuing to return capital to shareholders through dividends and share repurchases [Third Quarter 2025 Outlook](index=3&type=section&id=4.1_Third_Quarter_2025_Outlook) Aptar anticipates a solid Q3 2025, with continued strength in Pharma, particularly Injectables, driven by rising demand for higher value elastomeric components. The company expects adjusted earnings per share in the range of $1.53 to $1.61, factoring in higher legal fees and a lower effective tax rate - Expected adjusted earnings per share for Q3 2025: **$1.53 to $1.61**[14](index=14&type=chunk) - Guidance includes approximately **6 to 7 cents of higher legal fees** associated with litigating pharma intellectual property rights[14](index=14&type=chunk) - Expected effective tax rate range for Q3 2025: **20.5% to 22.5%**, primarily due to a one-time tax benefit, compared to 23.8% in Q3 2024[14](index=14&type=chunk) - Anticipates continued strength in Pharma, especially Injectables, driven by growth in biologics, GLP-1 therapies, and Annex 1 compliance requirements[14](index=14&type=chunk) - Expects challenges as naloxone sales begin to normalize and elevated cough and cold inventory in Europe persists[14](index=14&type=chunk) - Modest Q3 contributions are anticipated from Closures and Beauty segments, with a continued focus on cost discipline across all segments[14](index=14&type=chunk) [Cash Dividends and Share Repurchases](index=3&type=section&id=4.2_Cash_Dividends_Share_Repurchases) Aptar's Board of Directors approved a quarterly cash dividend of $0.45 per share. In the second quarter, the company repurchased 452 thousand shares for $70 million, contributing to a total of $210 million returned to shareholders in the first half of the year - Quarterly cash dividend approved: **$0.45 per share**, payable August 14, 2025[15](index=15&type=chunk) - Q2 2025 share repurchases: **452 thousand shares for $70 million**[15](index=15&type=chunk) - Total returned to shareholders in the first half of 2025: **$210 million**[3](index=3&type=chunk)[6](index=6&type=chunk)[15](index=15&type=chunk) [Company Information and Disclosures](index=3&type=section&id=5_Company_Information_Disclosures) This section provides essential information about AptarGroup, including its business overview, conference call details, non-GAAP measure definitions, and forward-looking statement disclaimers [About Aptar](index=3&type=section&id=5.1_About_Aptar) Aptar is a global leader in drug and consumer product dosing, dispensing, and protection technologies, serving diverse end markets including pharmaceutical, beauty, food, and personal care. The company is headquartered in Crystal Lake, Illinois, with over 13,000 employees in 20 countries - Global leader in drug and consumer product dosing, dispensing, and protection technologies[17](index=17&type=chunk) - Serves pharmaceutical, beauty, food, beverage, personal care, and home care markets[17](index=17&type=chunk) - Headquartered in Crystal Lake, Illinois, with more than **13,000 dedicated employees in 20 countries**[17](index=17&type=chunk) [Open Conference Call](index=3&type=section&id=5.2_Open_Conference_Call) Aptar will host a conference call on Friday, August 1, 2025, at 8:00 a.m. Central Time to discuss the company's second quarter 2025 results. Interested parties can listen via live webcast or access a replay on the Investor Relations website - Conference call scheduled for **Friday, August 1, 2025, at 8:00 a.m. Central Time**[16](index=16&type=chunk) - Purpose: Discuss second quarter 2025 results[16](index=16&type=chunk) - Access: Live webcast and replay available on investors.aptar.com[16](index=16&type=chunk) [Presentation of Non-GAAP Information](index=4&type=section&id=5.3_Presentation_of_Non_GAAP_Information) This section defines non-GAAP financial measures used in the press release, such as adjusted earnings per share, adjusted EBITDA, and core sales. These measures exclude the impact of restructuring, acquisition costs, investment gains/losses, and foreign currency effects to provide a clearer period-over-period comparison of core operating performance for investors and management - Non-GAAP financial measures include adjusted earnings per share, adjusted EBITDA, adjusted EBITDA margin, and core sales[18](index=18&type=chunk) - These measures exclude items such as restructuring initiatives, acquisition-related costs, certain purchase accounting adjustments, net unrealized investment gains/losses, and foreign currency translation effects[18](index=18&type=chunk) - Rationale: Provide useful information for investors by allowing a better period-over-period comparison of operating results and reflecting core operating performance[18](index=18&type=chunk) - Free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures[18](index=18&type=chunk) [Forward-Looking Statements](index=5&type=section&id=5.4_Forward_Looking_Statements) The press release contains forward-looking statements that are subject to various known and unknown risks and uncertainties, including geopolitical conflicts, cybersecurity threats, raw material availability, intellectual property litigation, economic conditions, competition, tariffs, and regulatory changes, which could cause actual results to differ materially from expectations - Forward-looking statements are based on beliefs and assumptions, and actual results may differ materially due to known or unknown risks and uncertainties[20](index=20&type=chunk) - Key risks include: geopolitical conflicts, cybersecurity threats, raw material and component availability, intellectual property rights litigation, economic conditions (inflation/recession), competition, tariffs, supply chain disruptions, foreign currency fluctuations, and changes in government regulation[20](index=20&type=chunk) - The company undertakes no obligation to update publicly any forward-looking statements, except as required by law[20](index=20&type=chunk) [Contacts](index=5&type=section&id=5.5_Contacts) Provides contact information for investor relations and media inquiries - Investor Relations Contact: Mary Skafidas, mary.skafidas@aptar.com, 815-479-5530[21](index=21&type=chunk) - Media Contact: Katie Reardon, katie.reardon@aptar.com, 815-479-5671[21](index=21&type=chunk) [Condensed Consolidated Financial Statements (Unaudited)](index=6&type=section&id=6_Condensed_Consolidated_Financial_Statements_Unaudited) This section presents AptarGroup's unaudited condensed consolidated financial statements, including statements of income and balance sheets, for the specified periods [Consolidated Statements of Income](index=6&type=section&id=6.1_Consolidated_Statements_of_Income) The unaudited condensed consolidated statements of income present AptarGroup's financial performance for the three and six months ended June 30, 2025 and 2024, showing increases in net sales, operating income, and net income for both periods Consolidated Statements of Income (Unaudited) | Metric (In Thousands) | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :------------------------------------------ | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Net Sales | $966,009 | $910,063 | $1,853,314 | $1,825,511 | | Operating Income | $144,393 | $126,010 | $257,841 | $238,093 | | Income before Income Taxes | $139,714 | $118,246 | $245,729 | $222,564 | | Net Income | $111,732 | $90,458 | $190,395 | $173,391 | | Diluted EPS | $1.67 | $1.34 | $2.83 | $2.57 | [Consolidated Balance Sheets](index=7&type=section&id=6.2_Consolidated_Balance_Sheets) The unaudited consolidated balance sheets show AptarGroup's financial position as of June 30, 2025, compared to December 31, 2024, with total assets increasing to $4.87 billion and total stockholders' equity rising to $2.72 billion Consolidated Balance Sheets (Unaudited) | Metric (In Thousands) | June 30, 2025 | December 31, 2024 | | :------------------------------------------ | :-------------- | :---------------- | | Total Current Assets | $1,663,020 | $1,478,383 | | Property, Plant and Equipment, Net | $1,584,533 | $1,447,150 | | Goodwill | $996,489 | $936,256 | | Total Assets | $4,865,381 | $4,432,278 | | Total Current Liabilities | $1,368,884 | $1,068,281 | | Total Liabilities | $2,147,567 | $1,946,354 | | Total Stockholders' Equity | $2,717,814 | $2,485,924 | [Non-GAAP Reconciliations (Unaudited)](index=8&type=section&id=7_Non_GAAP_Reconciliations_Unaudited) This section provides detailed reconciliations of GAAP to non-GAAP financial measures, including adjusted EBIT, EBITDA, and earnings per share, for transparent financial reporting [Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income](index=8&type=section&id=7.1_Reconciliation_of_Adjusted_EBIT_and_Adjusted_EBITDA_to_Net_Income) This section provides detailed reconciliations of reported net income to adjusted EBIT and adjusted EBITDA for both the three and six months ended June 30, 2025 and 2024, highlighting adjustments for restructuring initiatives, net investment gains/losses, and transaction costs related to acquisitions [Three Months Ended June 30, 2025 & 2024](index=8&type=section&id=7.1.1_Three_Months_Ended_June_30_2025_2024) This sub-section details the reconciliation of adjusted EBIT and EBITDA to net income for the second quarter of 2025 and 2024 Adjusted EBIT and EBITDA Reconciliation (Q2) | Metric (In Thousands) | Q2 2025 (Consolidated) | Q2 2024 (Consolidated) | | :-------------------------------------------------- | :--------------------- | :--------------------- | | Reported income before income taxes | $139,714 | $118,246 | | Adjustments (Restructuring, Net investment, Transaction costs) | (179) | 2,595 | | Adjusted earnings before income taxes | $139,535 | $120,841 | | Adjusted EBIT | $148,505 | $127,800 | | Adjusted EBITDA | $218,409 | $192,768 | | Adjusted EBITDA margins | 22.6% | 21.2% | [Six Months Ended June 30, 2025 & 2024](index=9&type=section&id=7.1.2_Six_Months_Ended_June_30_2025_2024) This sub-section details the reconciliation of adjusted EBIT and EBITDA to net income for the six months ended June 30, 2025 and 2024 Adjusted EBIT and EBITDA Reconciliation (YTD) | Metric (In Thousands) | YTD 2025 (Consolidated) | YTD 2024 (Consolidated) | | :-------------------------------------------------- | :---------------------- | :---------------------- | | Reported income before income taxes | $245,729 | $222,564 | | Adjustments (Restructuring, Net investment, Transaction costs) | 2,959 | 5,483 | | Adjusted earnings before income taxes | $248,688 | $228,047 | | Adjusted EBIT | $266,195 | $242,283 | | Adjusted EBITDA | $401,746 | $371,600 | | Adjusted EBITDA margins | 21.7% | 20.4% | [Reconciliation of Adjusted Earnings Per Diluted Share (Q2 & YTD)](index=10&type=section&id=7.2_Reconciliation_of_Adjusted_Earnings_Per_Diluted_Share_Q2_YTD) This reconciliation details the adjustments made to reported diluted earnings per share to arrive at adjusted diluted earnings per share for the three and six months ended June 30, 2025 and 2024, accounting for restructuring, net investment gains/losses, acquisition costs, and foreign currency effects Adjusted Earnings Per Diluted Share Reconciliation | Metric | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 | | :-------------------------------------------------- | :------ | :------ | :------- | :------- | | Reported Net Income Attributable to AptarGroup, Inc. Per Diluted Share | $1.67 | $1.34 | $2.83 | $2.57 | | Adjustments (Restructuring, Net investment, Transaction costs, FX) | (0.01) | 0.07 | 0.03 | 0.07 | | Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share | $1.66 | $1.41 | $2.86 | $2.64 | [Reconciliation of Free Cash Flow to Net Cash Provided by Operations](index=11&type=section&id=7.3_Reconciliation_of_Free_Cash_Flow_to_Net_Cash_Provided_by_Operations) This reconciliation shows AptarGroup's free cash flow for the three and six months ended June 30, 2025 and 2024, derived from net cash provided by operations after accounting for capital expenditures and proceeds from government grants Free Cash Flow Reconciliation (In Thousands) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :------------------------------------------ | :------------------------------- | :------------------------------- | :----------------------------- | :----------------------------- | | Net Cash Provided by Operations | $125,958 | $143,579 | $208,700 | $235,912 | | Capital Expenditures | (63,425) | (68,205) | (120,287) | (143,866) | | Proceeds from Government Grants | 3,308 | — | 3,308 | — | | Free Cash Flow | $65,841 | $75,374 | $91,721 | $92,046 | [Reconciliation of Adjusted Earnings Per Diluted Share (Q3 2025 Outlook)](index=12&type=section&id=7.4_Reconciliation_of_Adjusted_Earnings_Per_Diluted_Share_Q3_2025_Outlook) This reconciliation provides the basis for Aptar's third quarter 2025 adjusted earnings per diluted share guidance of $1.53 to $1.61, detailing adjustments to the prior year's reported earnings for restructuring, investment gains, and foreign currency effects, and noting the expected effective tax rate range Adjusted Earnings Per Diluted Share Reconciliation (Q3 Outlook) | Metric | Expected Q3 2025 (Adjusted) | Q3 2024 (Adjusted) | | :-------------------------------------------------- | :-------------------------- | :----------------- | | Adjusted Net Income Attributable to AptarGroup, Inc. | $104,192 | $104,192 | | Adjusted Net Income Attributable to AptarGroup, Inc. Per Diluted Share | $1.53 - $1.61 | $1.54 | - The expected earnings per share range for Q3 2025 is based on an effective tax rate range of **20.5% to 22.5%**, compared to the prior year's effective tax rate of 23.8%[34](index=34&type=chunk)

Company Overview - AptarGroup, Inc. (NYSE: ATR) designs and manufactures a wide variety of drug delivery and consumer product dispensing solutions for various end markets [1] - The company operates through three reportable segments: Pharma, Beauty, and Closures [1] - AptarGroup has a current market capitalization, indicating its size and market presence [1] Analyst Background - The analyst has a master's degree in Analytics from Northwestern University and a bachelor's degree in Accounting [1] - With over 10 years of experience in the investment arena, the analyst has progressed from an analyst role to a management position [1] - Dividend investing is a personal interest of the analyst, who aims to share insights with the Seeking Alpha community [1]

Industry Overview - The Zacks Containers - Paper and Packaging industry is experiencing weak demand due to lower consumer spending amid inflation, but pricing actions by industry players are expected to mitigate the impacts of supply-chain disruptions and elevated costs [1][4] - The industry is supported by rising e-commerce activities and increasing demand for sustainable packaging options due to environmental concerns [1][5] Market Dynamics - The industry has faced volume declines as consumers reduce spending and inventory levels, impacting top-line performance [4] - Supply-chain disruptions and higher costs for materials, labor, and transportation, along with tariffs, are adding pressure on margins [4] - Companies are implementing pricing strategies and cost-reduction actions to counter these challenges [4] Growth Opportunities - E-commerce is a significant growth catalyst, with global e-commerce revenues projected to grow at a CAGR of 18.9% from 2024 to 2030, and the U.S. market at 16.4% [5] - The industry has over 60% exposure to consumer-oriented markets, ensuring stable demand for packaging solutions across economic cycles [5] Environmental Trends - There is a growing preference for eco-friendly biodegradable packaging materials, driven by increased consumer awareness of environmental issues [6] - The industry is adopting new technologies and incorporating recycled content into production methods to enhance sustainability [6] Industry Performance - The Zacks Containers - Paper and Packaging industry ranks 155 out of 247 Zacks industries, placing it in the bottom 37% [7][8] - The industry has underperformed compared to its sector and the S&P 500, declining 9.7% over the past year, while the sector grew by 10.7% and the S&P 500 gained 16.1% [10] Current Valuation - The industry is currently trading at a trailing 12-month EV/EBITDA ratio of 20.84, higher than the S&P 500's 18.07 and the Industrial Products sector's 19.71 [13] - Over the past five years, the industry has traded between 17.53X and 28.12X, with a median of 21.29X [18] Company Highlights - **Greif (GEF)**: Aims for adjusted EBITDA of $1 billion by fiscal 2027, with a focus on higher-margin offerings and cost elimination initiatives [19][20] - **Brambles (BXBLY)**: Reported a 3% revenue growth to $4.9 billion in the first nine months of fiscal 2025, with expectations of 4-5% growth for the fiscal year [23][24] - **AptarGroup (ATR)**: Sees healthy demand in its Pharma segment and aims to expand through acquisitions, with a focus on resilient markets [27][28]

Industry Overview - The U.S. manufacturing sector is showing signs of recovery after a prolonged downturn, with new orders for manufactured goods increasing by 8.2% in May compared to a revised 3.9% decline in April, and a year-over-year increase of 3.2% [3][4] - The rebound in manufacturing activity is supported by easing inflationary pressures and expectations of Federal Reserve rate cuts, which are anticipated to boost demand [1][6][11] Manufacturing Activity - The Institute of Supply Management's manufacturing PMI rose to 49 in June from 48.5 in May, indicating a continued contraction but a rebound from a six-month low [5][6] - Manufacturing activity accounts for 10.2% of the U.S. economy, highlighting its significance [5] Stock Recommendations - Four stocks from the manufacturing sector are recommended for investment: Allegion plc (ALLE), AptarGroup, Inc. (ATR), Broadwind, Inc. (BWEN), and DXP Enterprises, Inc. (DXPE), all of which have strong earnings growth prospects and Zacks Rank of 1 (Strong Buy) or 2 (Buy) [2][11] Allegion plc (ALLE) - Allegion is a global provider of security products and solutions, with an expected earnings growth of 3.9% for the current year and a Zacks Rank 2 [8][9] AptarGroup, Inc. (ATR) - AptarGroup specializes in innovative dispensing and packaging solutions, with an expected earnings growth of 4.1% for the current year and a Zacks Rank 2 [12][13] Broadwind, Inc. (BWEN) - Broadwind is a precision manufacturer focused on clean tech, particularly in the U.S. wind energy sector, with an expected earnings growth of 60% for the current year and a Zacks Rank 2 [14][15] DXP Enterprises, Inc. (DXPE) - DXP Enterprises is a distributor providing innovative solutions to industrial customers, with an expected earnings growth rate of 17.5% for the current year and a Zacks Rank 2 [16][17]

Core Viewpoint - CytoSorbents Corporation is actively pursuing regulatory approvals for its DrugSorb™-ATR device, aimed at reducing perioperative bleeding in patients undergoing CABG surgery who are on the antiplatelet drug Brilinta® [1][4] Regulatory Updates - The FDA has scheduled an appeal hearing for CytoSorbents' supervisory review of its De Novo Request, with expectations to resolve deficiencies by the end of August 2025 [2] - Health Canada issued a Notice of Refusal for the Medical Device License application, prompting the company to file a Request for Reconsideration by July 25, 2025 [3] Product Overview - DrugSorb-ATR is designed to address a significant need in cardiac surgery by mitigating bleeding risks associated with Brilinta® [4] - The device has received FDA Breakthrough Device Designation for removing ticagrelor and other direct oral anticoagulants during cardiothoracic procedures [8] Company Background - CytoSorbents specializes in blood purification therapies for critical conditions, utilizing proprietary polymer bead technology to remove toxins from blood [5] - The company's lead product, CytoSorb®, is already approved in the EU and has been used over 270,000 times globally [6]

Group 1: Locate Technologies (ASX: LOC) - Locate Technologies' stock price surged by 42.86% to 0.25 AUD, with a market capitalization of 57.58 million AUD and 230 million shares issued [3] - The stock price increased from 0.115 AUD to a peak of 0.28 AUD, representing a 144% rise, with significant trading volume prompting inquiries from the Australian Stock Exchange [3][4] - The company has invested 1.62 million AUD in Bitcoin, continuing to allocate excess cash reserves towards this investment [4] Group 2: Astron Corporation (ASX: ATR) - Astron Corporation's stock price jumped by 47.13% to 0.64 AUD, with a market capitalization of 133 million AUD and 210 million shares issued [10] - The Victorian government approved the Donald rare earth sands project, which is expected to produce significant rare earth elements, enhancing the project's global importance [10] - The project has received all major regulatory approvals necessary for financing arrangements [10] Group 3: Li-S Energy (ASX: LIS) - Li-S Energy's stock price rose by 23.66% to 0.115 AUD, with a market capitalization of 73.62 million AUD and 640 million shares issued [14] - The company signed a collaboration and battery supply agreement with a leading defense technology company to test the performance and safety of its lithium-sulfur batteries in defense applications [14] - Li-S Energy plans to accelerate its entry into key global markets, including defense, with the installation of a 2MWh production and testing facility [14]

Core Viewpoint - CytoSorbents Corporation has filed a request for supervisory review with the FDA regarding the De Novo Denial Letter for its DrugSorb-ATR Device, which aims to reduce bleeding severity in CABG surgery patients on Brilinta® [1][2][7] Group 1: Company Overview - CytoSorbents Corporation specializes in blood purification technologies for treating life-threatening conditions in intensive care and cardiac surgery [5] - The company's proprietary technologies utilize biocompatible polymer beads to remove toxic substances from blood, applicable in various medical scenarios including sepsis and organ failure [5][6] - CytoSorbents' lead product, CytoSorb®, is CE Marked in the EU and has been used over 270,000 times globally [6] Group 2: Regulatory Developments - The FDA issued a De Novo Denial Letter on April 25, 2025, citing deficiencies that must be resolved before the DrugSorb-ATR can be authorized for U.S. commercialization [2][7] - The company has engaged with the FDA to clarify these deficiencies and believes that the supervisory review process will effectively address the concerns [2][4] - The appeals process typically results in a final decision approximately 60 days after filing, with the company optimistic about receiving a regulatory decision in 2025 [3][7] Group 3: Market Context - DrugSorb-ATR is designed to mitigate perioperative bleeding in patients undergoing high-risk surgeries while on antithrombotic medications [7] - The application for DrugSorb-ATR is also under advanced review by Health Canada, with the agency committed to issuing a decision despite current delays [4][7]

Core Insights - Earnings growth is crucial for organizational survival and profitability, influencing share prices significantly [1][2] - Companies like Agnico Eagle Mines Limited (AEM), AptarGroup, Inc. (ATR), and VICI Properties Inc. (VICI) are showcasing strong earnings growth [1][8] Earnings Estimates & Share Price Movements - Stock prices may decline despite earnings growth if they fail to meet market expectations, often followed by price rallies after earnings declines [2] - Earnings estimates are influenced by sales growth, product demand, competitive environment, profit margins, and cost control, serving as a valuable tool for investment decisions [3] Investment Strategies - Investors should focus on stocks with a history of earnings growth and rising quarterly and annual earnings estimates [4] - Screening measures include Zacks Rank, historical EPS growth, and recent estimate revisions to identify stocks with strong earnings growth potential [5][6][7] Company Highlights - **Agnico Eagle Mines**: Expected earnings growth rate of 43% for the current year, Zacks Rank 2 (Buy) [7][8] - **AptarGroup**: Expected earnings growth rate of 4.1% for the current year, Zacks Rank 1 (Strong Buy) [9][8] - **VICI Properties**: Expected earnings growth rate of 4% for the current year, Zacks Rank 2 (Buy) [10][8]

Core Viewpoint - AptarGroup (ATR) has received an upgrade to a Zacks Rank 1 (Strong Buy), indicating a positive outlook based on rising earnings estimates, which are crucial for stock price movements [1][2][4] Earnings Estimates and Stock Price Impact - Changes in a company's future earnings potential, reflected in earnings estimate revisions, are strongly correlated with near-term stock price movements, influenced by institutional investors [3] - The Zacks rating system effectively captures the power of earnings estimate revisions, making it a valuable tool for investors [5][6] AptarGroup's Earnings Outlook - AptarGroup is expected to earn $5.87 per share for the fiscal year ending December 2025, with no year-over-year change, but the Zacks Consensus Estimate has increased by 5.5% over the past three months [7] - The upgrade to Zacks Rank 1 places AptarGroup in the top 5% of Zacks-covered stocks, suggesting potential for higher stock movement in the near term [9]

Core Insights - ATR and Pratt & Whitney Canada are collaborating to develop advanced propulsion technology for regional turboprop aircraft, focusing on low-emission aviation and enhancing aircraft performance [1][2][3] Company Overview - ATR is the leading regional aircraft manufacturer, known for its ATR 42 and 72 models, which dominate the below 90-seat market segment [4] - Pratt & Whitney, a business unit of RTX, specializes in aircraft engines and has a long history of innovation in propulsion technologies [5][7] Collaboration Details - The partnership aims to improve fuel efficiency, durability, and operating costs of regional turboprop engines, building on the success of the PW127XT engine [2][3] - The companies will explore hybrid-electric propulsion as part of the feasibility study for ATR's next-generation aircraft concept, ATR 'EVO' [2][3] Performance Metrics - Approximately 1,300 ATR aircraft powered by Pratt & Whitney Canada engines are currently in service, with over 60 using the latest PW127XT-M model [3] - The PW127XT-M engines have achieved over 300,000 flying hours since their introduction in 2022, resulting in a 40% improvement in time on wing, 20% reduction in maintenance costs, and at least 3% improvement in fuel efficiency [3] Environmental Commitment - ATR aircraft emit 45% less CO2 compared to similar-sized regional jets, highlighting the company's focus on sustainability [4] - ATR has successfully operated the first commercial aircraft using 100% sustainable aviation fuel (SAF) in both engines [4]